-- 週五美股期貨開盤漲跌互現,此前標普500指數和那斯達克指數均創下4月收盤新高,中東局勢仍持續僵持。 道瓊工業指數期貨上漲0.3%,標普500指數期貨上漲0.1%,那斯達克指數期貨下跌0.2%。 週四,標普500指數上漲1%,收在7,209.01點,首次突破7,200點大關;那斯達克指數上漲0.9%,收在24892.31點,同樣創下新的收盤紀錄。 根據Axios週三報道,美國總統川普拒絕了伊朗的最新提議,並表示美國將繼續封鎖伊朗港口,直到伊朗政權同意一項能夠解決美國對其核子計畫擔憂的協議。 交易員們關注了最新一輪的財報,能源巨頭埃克森美孚(XOM)和雪佛龍(CVX)均公佈第一季度調整後盈利下降,但營收成長。 油價漲跌互現,近月全球基準北海布蘭特原油上漲0.5%,至每桶110.95美元;美國西德州中質原油下跌0.8%,至每桶104.21美元。 彭博社總結的預測顯示,將於美國東部時間上午9:45公佈的4月終值採購經理人製造業指數(PMI)預計將為54.0,與前值持平。 將於美國東部時間上午10:00公佈的4月供應管理協會(ISM)服務業指數預計將為53.2,高於前值的52.7。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.